gonadotropin-releasing hormone-III

Also Known As:

GnRH-III; GnRH3; gonadoliberin-3; gonadotropin-releasing hormone (GnRH)-III; lGnRH-III; lamprey GnRH-III; pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2; pyroglutamyl-histidyl-tryptophyl-seryl-histidyl-aspartyl-tryptophyl-lysyl-prolyl-glycinamide

Networked: 51 relevant articles (5 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Hypothalamic Hormones: 68
      - Pituitary Hormone-Releasing Hormones: 39
        Gonadotropin-Releasing Hormone: 10670
        gonadotropin-releasing hormone-III: 51
Amino Acids, Peptides, and Proteins: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - Pyrrolidinones: 162
      - Pyrrolidonecarboxylic Acid: 255
        gonadotropin-releasing hormone-III: 51

Experts

1.	Mező, Gábor: 15 articles (05/2022 - 01/2012)
2.	Manea, Marilena: 15 articles (01/2016 - 04/2007)
3.	Orbán, Erika: 7 articles (05/2015 - 04/2009)
4.	Kapuvári, Bence: 6 articles (09/2019 - 04/2007)
5.	Hegedüs, Rózsa: 6 articles (09/2019 - 10/2012)
6.	Vincze, Borbála: 6 articles (01/2016 - 04/2007)
7.	Sobhon, Prasert: 5 articles (01/2016 - 02/2008)
8.	Szabó, Ildikó: 5 articles (12/2015 - 04/2009)
9.	Mezo, Gábor: 5 articles (01/2012 - 04/2007)
10.	Halmos, Gábor: 4 articles (05/2022 - 10/2012)

Related Diseases

1.	Neoplasms (Cancer) 11/09/2018 - "The best candidate revealed an increased cancer cell growth inhibitory effect compared to our lead-compound GnRH-III-[⁴Lys(Bu),⁸Lys(Dau=Aoa)]. " 04/01/2001 - "The unique conformational properties of lGnRH-III may account for its specific anti cancer activity." 11/01/1998 - "GnRH-III specifically bound to receptors on cancer cells and recognized not only the high-, but also the low-affinity binding sites. " 10/10/1997 - "Replacement of pGlu1 with Ac-D-Trp appears to have a significantly deleterious effect on a unique conformation of GnRH-III which is responsible for its binding to the receptors on cancer cell lines and the resultant antitumor activity." 01/01/2018 - "[4Lys(Bu)]-GnRH-III(Dau=Aoa) possessing the butyryl side chain acting as a "second drug" proved to be the best candidate for targeted tumor therapy due to its cytotoxicity and immobilizing effect on tumor cell spreading. "
2.	Breast Neoplasms (Breast Cancer) 04/01/2007 - "GnRH-III was reported to have selective FSH-releasing activity in rats and significant anticancer potency on human breast cancer cells. " 03/01/2005 - "Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth." 01/01/2000 - "We synthesized the analogs of GnRH-III with effective selective antitumor activity which does not alter the ovarian cycle of rats but inhibits the colony-formation of human breast cancer cell lines and has a significant antiproliferative effect. " 09/25/2019 - "Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice." 09/25/2019 - "Moreover, the treatment with GnRH-III-Dau conjugates cause a significant in vivo tumor growth and metastases inhibitory effect in three different orthotopic models, including 4T1 mice and MDA-MB-231 human breast carcinoma, as well as HT-29 human colorectal cancer bearing BALB/s and SCID mice, while toxic side-effects were substantially reduced in comparison to the treatment with the free drug. "
3.	Prostatic Neoplasms (Prostate Cancer) 10/01/2013 - "Based on these observations, different cytotoxic GnRH-III bioconjugates have recently been synthesized; preliminary in vitro studies suggest that these compounds might represent a new promising treatment strategy for prostate cancer." 01/01/2012 - "We synthesized 21 lGnRH-III analogs with rational amino acid substitutions and studied their effect on PC3 and LNCaP prostate cancer cell proliferation. " 01/01/2015 - "Our results demonstrated that both Dau-GnRH-III and Dau-[4Lys(Ac)]-GnRH-III were rapidly internalized into DU145 prostate cancer cells and exerted a significant cytostatic effect. " 01/01/2015 - "Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor."
4.	Colorectal Neoplasms (Colorectal Cancer) 09/25/2019 - "Moreover, the treatment with GnRH-III-Dau conjugates cause a significant in vivo tumor growth and metastases inhibitory effect in three different orthotopic models, including 4T1 mice and MDA-MB-231 human breast carcinoma, as well as HT-29 human colorectal cancer bearing BALB/s and SCID mice, while toxic side-effects were substantially reduced in comparison to the treatment with the free drug. " 01/01/2016 - "Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice."
5.	Melanoma (Melanoma, Malignant) 01/01/2018 - "By studying the cell movement of A2058 cells with a holographic microscope, it was found that the migratory behavior of melanoma cells was increased by [4Lys(Ac)]-GnRH-III(Dau=Aoa), while the GnRH-III(Dau=Aoa) and [4Lys(Bu)]-GnRH-III(Dau=Aoa) decreased this activity. " 01/01/2018 - "Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids." 01/01/2018 - "Conclusion: Internalization and cytotoxicity of the conjugates showed that GnRH-III peptides could guard Dau to melanoma cells and promote antitumor activity. "

Related Drugs and Biologics

1.	Daunorubicin (Cerubidine)
2.	gonadotropin-releasing hormone-III
3.	Gonadotropin-Releasing Hormone (GnRH)
4.	Peptides (Polypeptides)
5.	Butyric Acid (Butanoic Acid)
6.	Volatile Fatty Acids
7.	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
8.	Cytostatic Agents
9.	Messenger RNA (mRNA)
10.	Hormones (Hormone)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Injections
4.	Castration
5.	Aftercare (After-Treatment)